Introducing the British Standards Institution’s new environmental initiative to minimize antimicrobial resistance caused by manufacturing operations.

Research sheds new light on cancer risk in gene therapies

What have we learned from an ever-evolving cell and gene therapy field?

Can yeast-based vaccines help overcome global vaccine inequity challenges?

Three companies – Cardinal Health, REGENXBIO, and Beacon Therapeutics – help us explore gene therapy development in the ophthalmic space

Nick Armstrong, Senior Director of Digital Enablement at CAI, discusses the realities of digital enablement, artificial intelligence, and more.

Can genetically engineering yeast be used to produce safe and scalable schizophrenia plant-inspired drugs?

Our roundup of some of our thoughtful and inspiring video interviews and roundtables from the past year.

Cerevel Therapeutics' Emraclidine - in development for schizophrenia and Alzheimer’s disease psychosis - yields positive results in phase Ib trial

Exploring the potential of hybrid peptide-DNA nanostructures and artificial life